Company intelligence / Profile preview

Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.

Guangzhou, Guangdong Sheng, China

Ownership: Private
Development stage: Other

Overview

The company has a Phase 3 clinical trial for Pozdeutinurad (AR882), a URAT1 inhibitor for the treatment of primary gout. A Phase 2/3 study comparing AR882 capsules to Febuxostat tablets in patients with primary gout and hyperuricemia was reported as "Active, not recruiting" as of September 20, 2024[9].

Therapeutic areas: Metabolic DisordersRheumatology
Modalities: Small molecule drugs
Industry: Biotech

Partnerships

Joint venture between Yipinhong Pharmaceutical Co., Ltd. (also referred to as Guangzhou Yipinhong Pharmaceutical Co., Ltd.) and Arthrosi Therapeutics, Inc.[1][2]

Beyond the preview

Go deeper on Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd..